Accelerate Diagnostics Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Accelerate Diagnostics (AXDX) Misses Q1 EPS by 8c
May 6, 2021 4:58 PM EDTAccelerate Diagnostics (NASDAQ: AXDX) reported Q1 EPS of ($0.41), $0.08 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $3.1 million.
For earnings history and earnings-related data on Accelerate Diagnostics (AXDX) click here.
... More